ATGGF (Actinogen Medical) Dividend Payout Ratio: 0.00 (As of Dec. 2025)


What is Actinogen Medical Dividend Payout Ratio?

Actinogen Medical ATGGF Dividend Payout Ratio is 0.00 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 134 Biotechnology companies, Actinogen Medical ranks worse than 746267.91% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Actinogen Medical's Dividend Payout Ratio for the months ended in Dec. 2025 was 0.00.

The historical rank and industry rank for Actinogen Medical's Dividend Payout Ratio or its related term are showing as below:


ATGGF's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-06-26), the Dividend Yield % of Actinogen Medical is 0.00%.

Actinogen Medical's Dividends per Share for the months ended in Dec. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Actinogen Medical (OTCPK:ATGGF) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Actinogen Medical Dividend Payout Ratio Related Terms


Actinogen Medical Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Actinogen Medical's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinogen Medical Dividend Payout Ratio Chart

Actinogen Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Actinogen Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ATGGF vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Actinogen Medical's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's Dividend Payout Ratio falls into.



Actinogen Medical Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Actinogen Medical's Dividend Payout Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Jun. 2025 )/ EPS without NRI (A: Jun. 2025 )
=0/ -0.003
=N/A

Actinogen Medical's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.002
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Actinogen Medical (ATGGF) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Actinogen Medical and its competitors. According to the industry distribution chart, Actinogen Medical ranks #999999 out of 134 companies in the Biotechnology industry.
Is Actinogen Medical's Dividend Payout Ratio too high?
Actinogen Medical's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Actinogen Medical ranks #999999 out of 134 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Actinogen Medical's Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Actinogen Medical ranks #999999 out of 134 companies for Dividend Payout Ratio. This places Actinogen Medical in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Actinogen Medical and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actinogen Medical's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinogen Medical stock overvalued right now?
Actinogen Medical (ATGGF) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Actinogen Medical (ATGGF), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinogen Medical Business Description

Other Exchanges 3AC:GermanyACW:Australia
Address 109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.